Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration (Q44574719)

4 December 2017

Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration (English)

1 reference

4 December 2017

0 references

Christine Thiffault

1

1 reference

4 December 2017

J William Langston

series ordinal

2

1 reference

4 December 2017

Donato A Di Monte

series ordinal

3

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

4 December 2017

Experimental Neurology

1 reference

4 December 2017

183

1 reference

4 December 2017

1

1 reference

4 December 2017

173-179

1 reference

Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Origins of catecholamine metabolites in monkey cerebrospinal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Reproducibility of monoamine metabolite measurements in human cerebrospinal fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Monoamine metabolite levels in CSF of SIV-infected rhesus monkeys (Macaca mulatta).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

CSF sulfoconjugated catecholamines in man: their relationship with plasma catecholamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Markers of dopamine metabolism in Parkinson's disease. The Parkinson Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

The cerebrospinal fluid oxidized NO metabolites, nitrite and nitrate, in Alzheimer's disease and vascular dementia of Binswanger type and multiple small infarct type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4886%2803%2900140-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-4886(03)00140-7

1 reference

4 December 2017

1 reference